This study investigated the factors accounting for the poor responses to anti-PD-1 therapy in HCC patients; however, some of our findings through data analysis require validation through more rigorous cell or animal experiments, as well as large-scale clinical samples. The gene discussed is PDCD1; the disease is hepatocellular carcinoma.